Moreover, Wilms tumor 1 (WT1) mutations were shown to reduce DNA methylation levels significantly in AML patients, conferring the same hypomethylation signature observed in patients harbouring TET2 mutations [5]. The gene discussed is WT1; the disease is acute myeloid leukemia.